TESARO Announces Presentations of Abstracts at the 2018

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
125
TESARO Announces Presentations of Abstracts at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
  • Investor briefing to be webcast from Chicago on Monday, June 4, 2018 at 6:15PM CT

WALTHAM, Mass., May 16, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO ), an oncology-focused biopharmaceutical company, today announced the presentation of five ZEJULA ® (niraparib) abstracts, including two oral presentations, at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 1 to June 5, 2018, in Chicago, Illinois. In addition, TESARO will webcast an investor and analyst briefing on Monday, June 4 at 6:15PM local time in conjunction with the ASCO Annual Meeting.

“TESARO has a targeted clinical development program to assess ZEJULA monotherapy activity in the front-line ovarian cancer setting and in combination with bevacizumab or anti-PD-1 in ovarian, breast and lung cancer,” said Mary Lynne Hedley, Ph.D., President and COO of TESARO. “At this year’s ASCO Annual Meeting, we look forward to oral presentations of results from the TOPACIO trial of niraparib plus anti-PD-1 in patients with triple-negative breast cancer or recurrent ovarian cancer, and a poster presentation of data from the QUADRA trial, which evaluated niraparib as a treatment for patients with advanced ovarian cancer.”  

Please plan to visit TESARO at Booth #10123 to learn more about ZEJULA, TSR-042 (anti-PD-1 antibody), TSR-022 (anti-TIM-3 antibody), and TSR-033 (anti-LAG-3 antibody).

Presentation Details:

Sunday, June 3, 2018, 9:45AM to 11:15AM  TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC): results from ROC cohort.  Oral Presentation; Abstract #106, 10:21AM, Location: Hall D1

Monday, June 4, 2018, 1:15PM to 4:45PM  Cost-effectiveness of niraparib versus routine surveillance, olaparib, and rucaparib for the maintenance treatment of adult patients with ovarian cancer in the United States.  Poster Presentation; Abstract #5559, Poster Board #286, Location: Hall A

Monday, June 4, 2018, 1:15PM to 4:45PM  OVARIO: The phase 2, single-arm, open-label study of maintenance therapy with niraparib + bevacizumab in patients with advanced ovarian cancer following response on frontline platinum- based chemotherapy.  Poster Presentation; Abstract #TPS5606, Poster Board #330a, Location: Hall A

Monday, June 4, 2018, 1:15PM to 4:45PM  QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received > 3 prior chemotherapy regimens.  Poster Presentation: Abstract #5514, Poster Board #241 Location: Hall A Poster Discussion: Monday, June 4, 4:45PM – 6:00PM; Location: S100bc

Monday, June 4, 2018, 3:00PM to 4:30PM  TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple- negative breast cancer (TNBC), a phase 2 trial.  Oral Presentation; Abstract #1011, 3:36PM, Location: Hall D2

Investor Briefing and Webcast TESARO will host an investor and analyst briefing in Chicago on Saturday, June 3 at 6:15 PM local time in conjunction with the ASCO Annual Meeting. A reception will begin at 6:00 PM CT, preceding the presentation. During this briefing, TESARO management will provide a business overview and pipeline update and will answer questions from investors and analysts. This event will be webcast live and archived for 30 days, and may be accessed from the TESARO Investor Events and Presentations webpage at www.tesarobio.com .

The TOPACIO trial is being conducted in collaboration with Merck Sharp & Dohme B.V., a subsidiary of Merck & Co., Inc., which is providing support for the trial.

About TESARO TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people facing cancer. For more information, visit www.tesarobio.com and follow us on Twitter and LinkedIn .

Investor/Media Contacts:  Jennifer Davis Vice President, Corporate Communications & Investor Relations +1.781.325.1116 or jdavis@tesarobio.com

Kate Rausch Associate Director, Investor Relations +1.781.257.2505 or krausch@tesarobio.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

HNTB Expands in Capital Region: A Strategic Move

Updated Category News Views 2

Breaking New Ground in Arlington and Baltimore Deepening their stake in the Capital Region's future, HNTB has thrown open new office doors in Arlington, Virginia, and Baltimore, Maryland. We're not just talking fancy buildings, folks—this is about securing a piece of the infrastructure pie that's only going to get bigger and tastier. Infrastructure's the backbone of...

Continue Reading
Lititz Mutual Embraces AI with Guidewire ProNavigator

Updated Category News Views 6

It's not every day you see a company like Lititz Mutual making moves in the artificial intelligence (AI) arena. Based out of Lititz, Pennsylvania, this insurance firm has decided to shake things up with Guidewire's ProNavigator AI assistant. Forging New Paths in Insurance Lititz Mutual is set to inject some serious tech into their operations. The goal? Make life easier...

Continue Reading
Molex's VersaBeam Mini Pushes AI Data Center Limits

Updated Category News Views 3

Game-Changer for AI Data Centers? Across the tech landscape, space is a premium, and Molex's new VersaBeam Mini arrives like a hail Mary in the fourth quarter. In AI data centers, squeezing down every single component counts—especially when optical density's in play. What we're seeing here is a potential paradigm shift. A 3x density improvement from a tiny 3.5 x 9 mm...

Continue Reading
NACD Honors Top Board Leaders with 2026 Awards

Updated Category News Views 13

Celebrating Boardroom Mavericks at NACD Gala September 2026 has brought some sparkling recognition to the elites guiding today's corporate governance landscapes. The National Association of Corporate Directors (NACD) has announced their Directorship 100 honorees, tipping their hats to stellar individuals firing on all cylinders in the boardroom. Who's Getting the Nod?...

Continue Reading
Navigating AI's New Era: Dresner's 2026 Findings

Updated Category News Views 7

Big Insights in the AI World of 2026 Well folks, if there's one thing making waves in the boardrooms this year, it's AI. Dresner Advisory Services just threw down a gauntlet for companies with their fresh batch of reports focused on the dizzying world of AI. They ripped right into it, exploring how firms can bag a heap of benefits and deal with the hurdles that come with...

Continue Reading
Annex Brands Grows with Bastrop's PostalAnnex Opening

Updated Category News Views 5

New PostalAnnex Location Opens in Bastrop, TX Here's a fresh chapter in the books for Annex Brands, Inc. They've just cut the ribbon on a brand spanking new PostalAnnex in Bastrop, Texas, handing the reins over to eager fresh faces, Chetan Modi and Karan Desai. And you know what? This ain't just any regular location. It's a one-stop-shop for anything you could need, from...

Continue Reading
U.N. Leaders Converge at NYSE, Forus Soars to $3B Valuation

Updated Category News Views 6

A Busy Morning at the NYSE with Key Guests and Global Events In a world where high-stakes diplomacy and roaring market bells go hand in hand, today brings the U.S. Secretary of State, Marco Rubio, to the New York Stock Exchange. With the 81st Session of the United Nations General Assembly shaking up the Big Apple, the city finds itself at the intersection of politics and...

Continue Reading
Tenera Care's Tech Triumph: Halving Falls with Simplicity

Updated Category News Views 6

Every once in a while, a piece of tech comes along that makes you sit up and say, ‘Now that’s a game-changer!’ And with the recent rave reviews, Tenera Care seems to hit just that sweet spot for folks in the senior living game. By handing Dublin Glenn Memory Care the gold in the KISS category at the 2026 McKnight's Technology Awards, it’s clear the industry is...

Continue Reading
Nature-Based Solutions: The Economic And Community Impact

Updated Category News Views 8

Harnessing Nature to Boost Economies You ever stop to think about how nature itself might just be the best investment? Well, the Walton Family Foundation surely does, betting big on nature-based solutions. Their latest initiative, 'Human Nature,' is shedding light on how these solutions aren't just saving ecosystems — they're fortifying economies and enriching...

Continue Reading
Lavior and CR Fitness Team for Wellness Reach

Updated Category News Views 2

Botanical Care Meets Gym Life in the Southeast Lavior, the botanical whiz kids of wound and skin care out of Miami, are shaking hands with CR Fitness, Crunch's big-time franchise operator carrying the flag across the Southeast. They’ve ironed out a deal that’ll park Lavior’s products in more than 60 gyms covering Florida, Georgia, North Carolina, and Texas. It’s a...

Continue Reading

Top 5 Most Recently Viewed Articles

WNS Holdings Reports Earnings Consistent with Estimates

Updated Category News Views 99

WNS Holdings Reports Earnings in Line with Expectations WNS Holdings (NYSE: WNS) has recently announced its earnings results for the third quarter, showcasing a steady performance. The company's earnings per share (EPS) matched analyst estimates at $1.04, demonstrating its capability to maintain projected profitability. The revenue for the quarter stood at $333 million,...

Continue Reading
Join the Class Action Against Avantor, Inc. Before the Deadline

Updated Category News Views 137

Class Action Notice for Avantor, Inc. (AVTR) Shareholders Attention, shareholders of Avantor, Inc. (NYSE: AVTR). A class action lawsuit has been filed, urging you to take action before the upcoming deadline. This notice serves to inform you about your rights and potential recovery options in light of the recent allegations against the company. Why Shareholders Should...

Continue Reading
Sanofi's Efdoralprin Alfa: A Breakthrough in AATD Treatment

Updated Category News Views 426

Sanofi's Efdoralprin Alfa: Advances in Alpha-1 Antitrypsin Deficiency Sanofi is making significant strides with efdoralprin alfa, a therapy that has shown great promise in treating alpha-1 antitrypsin deficiency (AATD) emphysema. In recent clinical trials, efdoralprin alfa successfully met all primary and key secondary endpoints, highlighting its potential as a...

Continue Reading
Corpse Reviver Beverage Now Available at Walmart Stores

Updated Category News Views 175

Expansion of Corpse Reviver in Walmart Stores Corpse Reviver has made significant strides since its launch in the United States. Just a short time following its debut, the brand is excited to share news of its availability in Walmart, the largest retail chain globally. This expansion marks a crucial step in enhancing the accessibility of Corpse Reviver's premium hydration...

Continue Reading
Exploring the Rise of Eco-Friendly Natural Dyes Industry

Updated Category News Views 249

Market Overview The natural dyes market is on a tremendous growth trajectory, expected to reach USD 8.95 billion within the next decade. This rise is primarily driven by a growing consumer inclination towards eco-friendly products. According to a recent report, the valuation of this market stood at USD 5.07 billion, indicating a compound annual growth rate (CAGR) of 5.9%...

Continue Reading